NCT05715606View on ClinicalTrials.gov

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

EARLY_PHASE1UnknownINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

February 1, 2025

Study Completion Date

May 15, 2025

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG

Metabolically Armed CD19 CAR-T cells

Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion

Trial Locations (1)

Unknown

RECRUITING

Anhui Provincial Hospital, Hefei

Sponsors

Collaborators (1)

Leman Biotech Co., Ltd.

All Listed Sponsors

collaborator

Leman Biotech Co., Ltd.

INDUSTRY

lead

Anhui Provincial Hospital

OTHER_GOV

NCT05715606 - Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research | Biotech Hunter | Biotech Hunter